{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:28:57Z","timestamp":1793363337844,"version":"4.5.0"},"reference-count":278,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["35059"],"award-info":[{"award-number":["35059"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-162164"],"award-info":[{"award-number":["PJT-162164"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-168865"],"award-info":[{"award-number":["PJT-168865"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41380-023-02230-9","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:02:23Z","timestamp":1695636143000},"page":"4070-4083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tau: a biomarker of Huntington\u2019s disease"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-3433","authenticated-orcid":false,"given":"Eva","family":"Lepinay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-1961","authenticated-orcid":false,"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"2230_CR1","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.3233\/JAD-2012-129031","volume":"33","author":"JZ Wang","year":"2013","unstructured":"Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis. 2013;33:S123\u201339.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/brain\/awx255","volume":"140","author":"G Cisbani","year":"2017","unstructured":"Cisbani G, Maxan A, Kordower JH, Planel E, Freeman TB, Cicchetti F. Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease. Brain. 2017;140:2982\u201392.","journal-title":"Brain."},{"key":"2230_CR3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/brain\/awv107","volume":"138","author":"R Vuono","year":"2015","unstructured":"Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, REGISTRY Investigators of the European Huntington\u2019s Disease Network, et al. The role of tau in the pathological process and clinical expression of Huntington\u2019s disease. Brain. 2015;138:1907\u201318.","journal-title":"Brain."},{"key":"2230_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/hmg\/ddu456","volume":"24","author":"M Gratuze","year":"2015","unstructured":"Gratuze M, No\u00ebl A, Julien C, Cisbani G, Milot-Rousseau P, Morin F, et al. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington\u2019s disease. Hum Mol Genet. 2015;24:86\u201399.","journal-title":"Hum Mol Genet"},{"key":"2230_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrneurol.2012.169","volume":"8","author":"R Wade-Martins","year":"2012","unstructured":"Wade-Martins R. Genetics: the MAPT locus\u2014a genetic paradigm in disease susceptibility. Nat Rev Neurol. 2012;8:477\u20138.","journal-title":"Nat Rev Neurol"},{"key":"2230_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/j.1460-2075.1989.tb03390.x","volume":"8","author":"M Goedert","year":"1989","unstructured":"Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8:393\u20139.","journal-title":"EMBO J"},{"key":"2230_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133:665\u2013704.","journal-title":"Acta Neuropathol"},{"key":"2230_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnagi.2019.00204","volume":"11","author":"P Barbier","year":"2019","unstructured":"Barbier P, Zejneli O, Martinho M, Lasorsa A, Belle V, Smet-Nocca C, et al. Role of tau as a microtubule-associated protein: structural and functional aspects. Front Aging Neurosci. 2019;11:204.","journal-title":"Front Aging Neurosci"},{"key":"2230_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/0028-3886.30420","volume":"55","author":"M Robert","year":"2007","unstructured":"Robert M, Mathuranath PS. Tau and tauopathies. Neurol India. 2007;55:11.","journal-title":"Neurol India"},{"key":"2230_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15295","volume":"8","author":"L Zhou","year":"2017","unstructured":"Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun. 2017;8:15295.","journal-title":"Nat Commun"},{"key":"2230_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/ijms19040998","volume":"19","author":"\u00c1 Sebasti\u00e1n-Serrano","year":"2018","unstructured":"Sebasti\u00e1n-Serrano \u00c1, De Diego-Garc\u00eda L, D\u00edaz-Hern\u00e1ndez M. The neurotoxic role of extracellular tau protein. Int J Mol Sci. 2018;19:998.","journal-title":"Int J Mol Sci"},{"key":"2230_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"LM Ittner","year":"2010","unstructured":"Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, Eersel J, et al. Dendritic function of tau mediates amyloid-\u03b2 toxicity in Alzheimer\u2019s disease mouse models. Cell. 2010;142:387\u201397.","journal-title":"Cell."},{"key":"2230_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.neuint.2010.12.023","volume":"58","author":"L Martin","year":"2011","unstructured":"Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer\u2019s disease. Neurochem Int. 2011;58:458\u201371.","journal-title":"Neurochem Int"},{"key":"2230_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","volume":"3","author":"M Goedert","year":"1989","unstructured":"Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease. Neuron. 1989;3:519\u201326.","journal-title":"Neuron."},{"key":"2230_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","volume":"33","author":"L Bu\u00e9e","year":"2000","unstructured":"Bu\u00e9e L, Bussi\u00e8re T, Bu\u00e9e-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 2000;33:95\u2013130.","journal-title":"Brain Res Rev"},{"key":"2230_CR16","unstructured":"Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer disease. In: StatPearls [Internet]. StatPearls Publishing; 2022."},{"key":"2230_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/archneur.58.3.373","volume":"58","author":"N Andreasen","year":"2001","unstructured":"Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373\u20139.","journal-title":"Arch Neurol"},{"key":"2230_CR18","doi-asserted-by":"publisher","unstructured":"Galasko D. Cerebrospinal fluid levels of A\u03b242 and tau: potential markers of Alzheimer\u2019s disease. In: Jellinger K, Fazekas F, Windisch M, editors. Ageing and dementia. Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, vol. 53). Vienna: Springer; 1998. https:\/\/doi.org\/10.1007\/978-3-7091-6467-9_19.","DOI":"10.1007\/978-3-7091-6467-9_19"},{"key":"2230_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1212\/WNL.45.4.788","volume":"45","author":"C Vigo-Pelfrey","year":"1995","unstructured":"Vigo-Pelfrey C, Seubert PP, Barbour R, Blomquist C, Lee M, Lee D, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. Neurology. 1995;45:788\u201393.","journal-title":"Neurology."},{"key":"2230_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry. 2019;24:1112\u201334.","journal-title":"Mol Psychiatry"},{"key":"2230_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.115.164848","volume":"57","author":"R Harada","year":"2016","unstructured":"Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208\u201314.","journal-title":"J Nucl Med"},{"key":"2230_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/j.semnuclmed.2016.09.006","volume":"47","author":"VL Villemagne","year":"2017","unstructured":"Villemagne VL, Dor\u00e9 V, Bourgeat P, Burnham SC, Laws S, Salvado O, et al. A\u03b2-amyloid and tau imaging in dementia. Semin Nucl Med. 2017;47:75\u201388.","journal-title":"Semin Nucl Med"},{"key":"2230_CR23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","volume":"79","author":"M Maruyama","year":"2013","unstructured":"Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094\u2013108.","journal-title":"Neuron."},{"key":"2230_CR24","doi-asserted-by":"publisher","first-page":"e0158460","DOI":"10.1371\/journal.pone.0158460","volume":"11","author":"SN Lockhart","year":"2016","unstructured":"Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, et al. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer\u2019s disease patients measured using [18F] THK-5351. PLoS ONE. 2016;11:e0158460.","journal-title":"PLoS ONE"},{"key":"2230_CR25","doi-asserted-by":"crossref","unstructured":"Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7:37.","DOI":"10.1186\/s40478-019-0686-6"},{"key":"2230_CR26","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.118.209916","volume":"59","author":"DF Wong","year":"2018","unstructured":"Wong DF, Comley RA, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, et al. Characterization of 3 novel tau radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in healthy controls and in Alzheimer subjects. J Nucl Med. 2018;59:1869\u201376.","journal-title":"J Nucl Med"},{"key":"2230_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60:93\u20139.","journal-title":"J Nucl Med"},{"key":"2230_CR28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00259-021-05401-4","volume":"48","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N, et al. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging. 2021;48:2295\u2013305.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2230_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2967\/jnumed.117.197426","volume":"59","author":"R Harada","year":"2018","unstructured":"Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, et al. Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med. 2018;59:671\u20134.","journal-title":"J Nucl Med"},{"key":"2230_CR30","doi-asserted-by":"crossref","unstructured":"Marqui\u00e9 M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787\u2013800.","DOI":"10.1002\/ana.24517"},{"key":"2230_CR31","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2967\/jnumed.115.170027","volume":"57","author":"S Shcherbinin","year":"2016","unstructured":"Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, et al. Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med. 2016;57:1535\u201342.","journal-title":"J Nucl Med"},{"key":"2230_CR32","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"C Xia","year":"2013","unstructured":"Xia C, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimers Dement. 2013;9:666\u201376.","journal-title":"Alzheimers Dement"},{"key":"2230_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","volume":"109","author":"K Tagai","year":"2021","unstructured":"Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and non-Alzheimer\u2019s disease tauopathies. Neuron. 2021;109:42\u201358.e8.","journal-title":"Neuron."},{"key":"2230_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau PET imaging in aging and early Alzheimer\u2019s disease. Ann Neurol. 2016;79:110\u20139.","journal-title":"Ann Neurol"},{"key":"2230_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/hbm.23874","volume":"39","author":"JS Phillips","year":"2017","unstructured":"Phillips JS, Das SR, McMillan CT, Irwin DJ, Roll EE, Da Re F, et al. Tau PET imaging predicts cognition in atypical variants of Alzheimer\u2019s disease. Hum Brain Mapp. 2017;39:691\u2013708.","journal-title":"Hum Brain Mapp"},{"key":"2230_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.arr.2017.03.002","volume":"36","author":"B Hall","year":"2017","unstructured":"Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O\u2019Brien JT. In vivo tau PET imaging in dementia: pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev. 2017;36:50\u201363.","journal-title":"Ageing Res Rev"},{"key":"2230_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain."},{"key":"2230_CR38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","volume":"142","author":"MJ Pontecorvo","year":"2019","unstructured":"Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia. Brain. 2019;142:1723\u201335.","journal-title":"Brain."},{"key":"2230_CR39","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-200808","volume":"80","author":"MD Devous Sr","year":"2021","unstructured":"Devous MD Sr, Fleisher AS, Pontecorvo MJ, Lu M, Siderowf A, Navitsky M, et al. Relationships between cognition and neuropathological tau in Alzheimer\u2019s disease assessed by 18F flortaucipir PET. J Alzheimers Dis. 2021;80:1091\u2013104.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/jnnp-2021-328623","volume":"93","author":"J Lagarde","year":"2022","unstructured":"Lagarde J, Olivieri P, Tonietto M, Tissot C, Rivals I, Gervais P, et al. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2022;93:459\u201367.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2230_CR41","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain. 2017;140:3286\u2013300.","journal-title":"Brain."},{"key":"2230_CR42","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awz019","volume":"142","author":"BA Gordon","year":"2019","unstructured":"Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, et al. Tau PET in autosomal dominant Alzheimer\u2019s disease: relationship with cognition, dementia and other biomarkers. Brain. 2019;142:1063\u201376.","journal-title":"Brain."},{"key":"2230_CR43","doi-asserted-by":"crossref","unstructured":"Lu J, Bao W, Li M, Li L, Zhang Z, Alberts I, et al. Associations of [18F]-APN-1607 tau PET binding in the brain of Alzheimer\u2019s disease patients with cognition and glucose metabolism. Front Neurosci. 2020;14:604.","DOI":"10.3389\/fnins.2020.00604"},{"key":"2230_CR44","doi-asserted-by":"crossref","unstructured":"Chen SD, Lu JY, Li HQ, Yang YX, Jiang JH, Cui M, et al. Staging tau pathology with tau PET in Alzheimer\u2019s disease: a longitudinal study. Transl Psychiatry. 2021;11:483.","DOI":"10.1038\/s41398-021-01602-5"},{"key":"2230_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2016.5755","volume":"74","author":"C Xia","year":"2017","unstructured":"Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74:427\u201336.","journal-title":"JAMA Neurol"},{"key":"2230_CR46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","volume":"87","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87:375\u201383.","journal-title":"Neurology."},{"key":"2230_CR47","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2967\/jnumed.117.194282","volume":"59","author":"IM Nasrallah","year":"2018","unstructured":"Nasrallah IM, Chen YJ, Hsieh MK, Phillips JS, Ternes K, Stockbower GE, et al. 18F-Flortaucipir PET\/MRI correlations in nonamnestic and amnestic variants of Alzheimer disease. J Nucl Med. 2018;59:299\u2013306.","journal-title":"J Nucl Med"},{"key":"2230_CR48","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamaneurol.2020.5505","volume":"78","author":"M Lu","year":"2021","unstructured":"Lu M, Pontecorvo MJ, Devous MD, Arora AK, Galante N, McGeehan A, et al. Aggregated tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and Alzheimer disease. JAMA Neurol. 2021;78:445\u201353.","journal-title":"JAMA Neurol"},{"key":"2230_CR49","doi-asserted-by":"crossref","unstructured":"Zhao Q, Liu M, Ha L, Zhou Y, Weiner MW, Alzheimer\u2019s Disease Neuroimaging Initiative, et al. Quantitative 18F-AV1451 brain tau PET imaging in cognitively normal older adults, mild cognitive impairment, and Alzheimer\u2019s disease patients. Front Neurol. 2019;10:486.","DOI":"10.3389\/fneur.2019.00486"},{"key":"2230_CR50","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-019-0510-3","volume":"11","author":"T Timmers","year":"2019","unstructured":"Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, et al. Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer\u2019s disease spectrum. Alzheimers Res Ther. 2019;11:60.","journal-title":"Alzheimers Res Ther"},{"key":"2230_CR51","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","volume":"26","author":"M Bucci","year":"2021","unstructured":"Bucci M, Chiotis K, Nordberg A. Alzheimer\u2019s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021;26:5888\u201398.","journal-title":"Mol Psychiatry"},{"key":"2230_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13195-021-00880-x","volume":"13","author":"D Biel","year":"2021","unstructured":"Biel D, Brendel M, Rubinski A, Buerger K, Janowitz D, Dichgans M, et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res Ther. 2021;13:137.","journal-title":"Alzheimers Res Ther"},{"key":"2230_CR53","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961\u201371.","journal-title":"JAMA Neurol"},{"key":"2230_CR54","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. Neuroimage. 2017;157:448\u201363.","journal-title":"Neuroimage."},{"key":"2230_CR55","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13195-022-01105-5","volume":"14","author":"D Biel","year":"2022","unstructured":"Biel D, Luan Y, Brendel M, Hager P, Dewenter A, Moscoso A, et al. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:166.","journal-title":"Alzheimers Res Ther"},{"key":"2230_CR56","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jalz.2018.12.001","volume":"15","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Insel PS, Donohue M, J\u00f6gi J, Ossenkoppele R, Olsson T, et al. Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer\u2019s disease. Alzheimers Dement. 2019;15:570\u201380.","journal-title":"Alzheimers Dement"},{"key":"2230_CR57","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3233\/JAD-170129","volume":"60","author":"I Koychev","year":"2017","unstructured":"Koychev I, Gunn RN, Firouzian A, Lawson J, Zamboni G, Ridha B, et al. PET tau and amyloid-\u03b2 burden in mild Alzheimer\u2019s disease: divergent relationship with age, cognition, and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2017;60:283\u201393.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR58","doi-asserted-by":"publisher","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","volume":"12","author":"R La Joie","year":"2020","unstructured":"La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12:eaau5732.","journal-title":"Sci Transl Med"},{"key":"2230_CR59","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ll M, Ossenkoppele R, Strandberg O, Palmqvist S, J\u00f6gi J, The Swedish BioFINDER study, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer\u2019s disease. Brain. 2017;140:2286\u201394.","DOI":"10.1093\/brain\/awx171"},{"key":"2230_CR60","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, Lockhart SN, Schonhaut DR, O\u2019Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971\u201382.","journal-title":"Neuron."},{"key":"2230_CR61","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack","year":"2018","unstructured":"Jack CR, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain. 2018;141:1517\u201328.","journal-title":"Brain."},{"key":"2230_CR62","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamaneurol.2016.2078","volume":"73","author":"L Wang","year":"2016","unstructured":"Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, et al. Evaluation of Tau imaging in staging Alzheimer disease and revealing interactions between \u03b2-amyloid and tauopathy. JAMA Neurol. 2016;73:1070\u20137.","journal-title":"JAMA Neurol"},{"key":"2230_CR63","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","volume":"31","author":"PE Kinahan","year":"2010","unstructured":"Kinahan PE, Fletcher JW. PET\/CT standardized uptake values (SUVs) in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31:496\u2013505.","journal-title":"Semin Ultrasound CT MR"},{"key":"2230_CR64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25.","journal-title":"Alzheimers Res Ther"},{"key":"2230_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, Dor\u00e9 V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14:225\u201336.","journal-title":"Nat Rev Neurol"},{"key":"2230_CR66","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ana.410380414","volume":"38","author":"H Arai","year":"1995","unstructured":"Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer\u2019s disease. Ann Neurol. 1995;38:649\u201352.","journal-title":"Ann Neurol"},{"key":"2230_CR67","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0304-3940(95)11297-A","volume":"186","author":"M Jensen","year":"1995","unstructured":"Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer\u2019s disease. Neurosci Lett. 1995;186:189\u201391.","journal-title":"Neurosci Lett"},{"key":"2230_CR68","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3233\/JAD-2011-101911","volume":"25","author":"TT Sepp\u00e4l\u00e4","year":"2011","unstructured":"Sepp\u00e4l\u00e4 TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. Longitudinal changes of CSF biomarkers in Alzheimer\u2019s disease. J Alzheimers Dis. 2011;25:583\u201394.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR69","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1111\/j.1471-4159.1993.tb09823.x","volume":"61","author":"M Vandermeeren","year":"1993","unstructured":"Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin JJ, et al. Detection of proteins in normal and Alzheimer\u2019s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61:1828\u201334.","journal-title":"J Neurochem"},{"key":"2230_CR70","first-page":"10","volume":"1","author":"L Rozenstein-Tsalkovich","year":"2014","unstructured":"Rozenstein-Tsalkovich L, Kahana E, Shenker A, Baitcher F, Cohen O, Kahana-Merhavi S, et al. CSF tau protein in Alzheimer\u2019s disease and other neurological and psychiatric diseases. Austin Alzheimers J Parkinsons Dis. 2014;1:10.","journal-title":"Austin Alzheimers J Parkinsons Dis"},{"key":"2230_CR71","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.biopsych.2004.07.021","volume":"56","author":"T Sunderland","year":"2004","unstructured":"Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, et al. Cerebrospinal fluid \u03b2-amyloid1\u201342 and tau in control subjects at risk for Alzheimer\u2019s disease: the effect of APOE \u03b54 allele. Biol Psychiatry. 2004;56:670\u20136.","journal-title":"Biol Psychiatry"},{"key":"2230_CR72","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.neurobiolaging.2005.06.005","volume":"27","author":"B Ibach","year":"2006","unstructured":"Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, et al. Cerebrospinal fluid tau and \u03b2-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging. 2006;27:1202\u201311.","journal-title":"Neurobiol Aging"},{"key":"2230_CR73","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","volume":"289","author":"T Sunderland","year":"2003","unstructured":"Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased \u03b2-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. J Am Med Assoc. 2003;289:2094\u2013103.","journal-title":"J Am Med Assoc"},{"key":"2230_CR74","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1242\/bio.20135447","volume":"2","author":"RJL Kandimalla","year":"2013","unstructured":"Kandimalla RJL, Prabhakar S, Wani WY, Kaushal A, Gupta N, Sharma DR, et al. CSF p-Tau levels in the prediction of Alzheimer\u2019s disease. Biol Open. 2013;2:1119\u201324.","journal-title":"Biol Open"},{"key":"2230_CR75","doi-asserted-by":"publisher","first-page":"116756","DOI":"10.1016\/j.jns.2020.116756","volume":"412","author":"LQ Ye","year":"2020","unstructured":"Ye LQ, Li XY, Zhang YB, Cheng HR, Ma Y, Chen DF, et al. The discriminative capacity of CSF \u03b2-amyloid 42 and tau in neurodegenerative diseases in the Chinese population. J Neurol Sci. 2020;412:116756.","journal-title":"J Neurol Sci"},{"key":"2230_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/00002093-199809000-00015","volume":"12","author":"P Mecocci","year":"1998","unstructured":"Mecocci P, Cherubini A, Bregnocchi M, Chionne F, Cecchetti R, Lowenthal DT, et al. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis Assoc Disord. 1998;12:211\u20134.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2230_CR77","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231\u201345.","journal-title":"Mol Chem Neuropathol"},{"key":"2230_CR78","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/archneur.60.12.1696","volume":"60","author":"CM Clark","year":"2003","unstructured":"Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and \u03b2-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696\u2013702.","journal-title":"Arch Neurol"},{"key":"2230_CR79","doi-asserted-by":"publisher","first-page":"376","DOI":"10.5935\/1676-2444.20150059","volume":"51","author":"CA Magalh\u00e3es","year":"2015","unstructured":"Magalh\u00e3es CA, Figueir\u00f3 M, Fraga VG, Mateo EC, Toledo AASF, Carvalho MDG, et al. Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer\u2019s disease. J Bras Patol Med Lab. 2015;51:376\u201382.","journal-title":"J Bras Patol Med Lab"},{"key":"2230_CR80","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s100720170055","volume":"22","author":"L Parnetti","year":"2001","unstructured":"Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F, et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer\u2019s disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci. 2001;22:77\u20138.","journal-title":"Neurol Sci"},{"key":"2230_CR81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95\u2013102.","journal-title":"Arch Gen Psychiatry"},{"key":"2230_CR82","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jnnp.2009.197483","volume":"81","author":"K Kasuga","year":"2010","unstructured":"Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, et al. Differential levels of \u03b1-synuclein, \u03b2-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2010;81:608\u201310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2230_CR83","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/jnnp.59.3.280","volume":"59","author":"RE Tato","year":"1995","unstructured":"Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1995;59:280\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2230_CR84","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JAD-140240","volume":"42","author":"D Alcolea","year":"2014","unstructured":"Alcolea D, Carmona-Iragui M, Su\u00e1rez-Calvet M, S\u00e1nchez-Saudin\u00f3s MB, Sala I, Ant\u00f3n-Aguirre S, et al. Relationship between \u03b2-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer\u2019s disease. J Alzheimers Dis. 2014;42:157\u201367.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR85","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1515\/CCLM.2006.258","volume":"44","author":"H Vanderstichele","year":"2006","unstructured":"Vanderstichele H, Vreese KD, Blennow K, Andreasen N, Sindic C, Ivanoiu A, et al. Analytical performance and clinical utility of the INNOTEST\u00ae PHOSPHO-TAU(181P) assay for discrimination between Alzheimer\u2019s disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006;44:1472\u201380.","journal-title":"Clin Chem Lab Med"},{"key":"2230_CR86","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/00002093-199812000-00020","volume":"12","author":"A Kurz","year":"1998","unstructured":"Kurz A, Riemenschneider M, Buch K, Willoch F, Bartenstein P, M\u00fcller U, et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis Assoc Disord. 1998;12:372\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2230_CR87","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","volume":"91","author":"E McDade","year":"2018","unstructured":"McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91:e1295\u2013306.","journal-title":"Neurology."},{"key":"2230_CR88","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804.","journal-title":"N Engl J Med"},{"key":"2230_CR89","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaneurol.2015.0098","volume":"72","author":"RP Almeida","year":"2015","unstructured":"Almeida RP, Schultz SA, Austin BP, Boots EA, Dowling NM, Gleason CE, et al. Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease. JAMA Neurol. 2015;72:699\u2013706.","journal-title":"JAMA Neurol"},{"key":"2230_CR90","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid \u03b2-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382\u20139.","journal-title":"Arch Neurol"},{"key":"2230_CR91","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.24186","volume":"76","author":"J Fortea","year":"2014","unstructured":"Fortea J, Vilaplana E, Alcolea D, Carmona-Iragui M, S\u00e1nchez-Saudinos MB, Sala I, et al. Cerebrospinal fluid \u03b2-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol. 2014;76:223\u201330.","journal-title":"Ann Neurol"},{"key":"2230_CR92","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11:e11170.","DOI":"10.15252\/emmm.201911170"},{"key":"2230_CR93","first-page":"136","volume":"34","author":"PA Thomann","year":"2009","unstructured":"Thomann PA, Kaiser E, Sch\u00f6nknecht P, Pantel J, Essig M, Schr\u00f6der J. Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci. 2009;34:136\u201342.","journal-title":"J Psychiatry Neurosci"},{"key":"2230_CR94","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/joim.12164","volume":"275","author":"X Li","year":"2014","unstructured":"Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer\u2019s disease. J Intern Med. 2014;275:418\u201327.","journal-title":"J Intern Med"},{"key":"2230_CR95","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1212\/WNL.0b013e3182563bd0","volume":"78","author":"TT Sepp\u00e4l\u00e4","year":"2012","unstructured":"Sepp\u00e4l\u00e4 TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 2012;78:1568\u201375.","journal-title":"Neurology."},{"key":"2230_CR96","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med. 2009;1:371\u201380.","journal-title":"EMBO Mol Med"},{"key":"2230_CR97","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger K, Ewers M, Pirttil\u00e4 T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain. 2006;129:3035\u201341.","journal-title":"Brain."},{"key":"2230_CR98","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1016\/j.jalz.2006.05.978","volume":"2","author":"SK Herukka","year":"2006","unstructured":"Herukka SK, Pennanen C, Soininen H, Pirttil\u00e4 T. P2\u2013140: cerebrospinal fluid A\u03b242, tau and phosphorylated tau correlate with hippocampal atrophy. Alzheimers Dement. 2006;2:S274.","journal-title":"Alzheimers Dement"},{"key":"2230_CR99","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","volume":"74","author":"\u00c5K Wallin","year":"2010","unstructured":"Wallin \u00c5K, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74:1531\u20137.","journal-title":"Neurology."},{"key":"2230_CR100","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000216841","volume":"27","author":"ES Blom","year":"2009","unstructured":"Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, et al. Rapid progression from mild cognitive impairment to Alzheimer\u2019s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4\/epsilon4 genotype. Dement Geriatr Cogn Disord. 2009;27:458\u201364.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2230_CR101","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave P, Minthon L, Zetterberg H, Wallin \u00c5K, Blennow K, Hansson O. Cerebrospinal fluid levels of \u03b2-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69:98\u2013106.","journal-title":"Arch Gen Psychiatry"},{"key":"2230_CR102","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1212\/01.wnl.0000286944.22262.ff","volume":"69","author":"M Ewers","year":"2007","unstructured":"Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology. 2007;69:2205\u201312.","journal-title":"Neurology."},{"key":"2230_CR103","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jns.2006.09.014","volume":"251","author":"A Stefani","year":"2006","unstructured":"Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci. 2006;251:124\u20138.","journal-title":"J Neurol Sci"},{"key":"2230_CR104","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neurobiolaging.2005.01.011","volume":"27","author":"RB Maccioni","year":"2006","unstructured":"Maccioni RB, Lavados M, Guill\u00f3n M, Mujica C, Bosch R, Far\u00edas G, et al. Anomalously phosphorylated tau and A\u03b2 fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging. 2006;27:237\u201344.","journal-title":"Neurobiol Aging"},{"key":"2230_CR105","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.arcmed.2005.03.036","volume":"36","author":"M Lavados","year":"2005","unstructured":"Lavados M, Far\u00edas G, Rothhammer F, Guillon M, Mujica MC, Maccioni C, et al. ApoE alleles and tau markers in patients with different levels of cognitive impairment. Arch Med Res. 2005;36:474\u20139.","journal-title":"Arch Med Res"},{"key":"2230_CR106","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/sj.mp.4001473","volume":"9","author":"H Hampel","year":"2004","unstructured":"Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF \u03b2-amyloid 1\u201342 and tau as predictors of Alzheimer\u2019s disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705\u201310.","journal-title":"Mol Psychiatry"},{"key":"2230_CR107","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385\u201393.","journal-title":"JAMA."},{"key":"2230_CR108","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archneur.59.11.1729","volume":"59","author":"M Riemenschneider","year":"2002","unstructured":"Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and \u03b2-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59:1729\u201334.","journal-title":"Arch Neurol"},{"key":"2230_CR109","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol"},{"key":"2230_CR110","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3233\/JAD-2011-111349","volume":"29","author":"L Parnetti","year":"2012","unstructured":"Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, et al. Performance of A\u03b2 1-40, A\u03b2 1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis. 2012;29:229\u201338.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR111","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1212\/WNL.0b013e3181af79fb","volume":"73","author":"P Vemuri","year":"2009","unstructured":"Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73:294\u2013301.","journal-title":"Neurology."},{"key":"2230_CR112","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.neurobiolaging.2007.08.010","volume":"30","author":"M Brys","year":"2009","unstructured":"Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30:682\u201390.","journal-title":"Neurobiol Aging"},{"key":"2230_CR113","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1097\/00001756-199911260-00005","volume":"10","author":"L Molina","year":"1999","unstructured":"Molina L, Touchon J, Herp\u00e9 M, Lefranc D, Duplan L, Cristol JP, et al. Tau and apo E in CSF: potential aid for discriminating Alzheimer\u2019s disease from other dementias. NeuroReport. 1999;10:3491.","journal-title":"NeuroReport."},{"key":"2230_CR114","doi-asserted-by":"publisher","first-page":"629","DOI":"10.7754\/Clin.Lab.2013.130440","volume":"60","author":"V De Riva","year":"2014","unstructured":"De Riva V, Galloni E, Marcon M, Di Dionisio L, Deluca C, Meligrana L, et al. Analysis of combined CSF biomarkers in AD diagnosis. Clin Lab. 2014;60:629\u201334.","journal-title":"Clin Lab"},{"key":"2230_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34129-4","volume":"13","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D, et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nat Commun. 2022;13:6635.","journal-title":"Nat Commun"},{"key":"2230_CR116","doi-asserted-by":"publisher","first-page":"e76523","DOI":"10.1371\/journal.pone.0076523","volume":"8","author":"JEJ Meredith","year":"2013","unstructured":"Meredith JEJ, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, et al. Characterization of novel CSF tau and ptau biomarkers for Alzheimer\u2019s disease. PLoS ONE. 2013;8:e76523.","journal-title":"PLoS ONE"},{"key":"2230_CR117","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","volume":"137","author":"C Cicognola","year":"2019","unstructured":"Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease. Acta Neuropathol. 2019;137:279\u201396.","journal-title":"Acta Neuropathol"},{"key":"2230_CR118","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/alz.12406","volume":"18","author":"AC van Harten","year":"2022","unstructured":"van Harten AC, Wiste HJ, Weigand SD, Mielke MM, Kremers WK, Eichenlaub U, et al. Detection of Alzheimer\u2019s disease amyloid beta 1-42, p-tau, and t-tau assays. Alzheimers Dement. 2022;18:635\u201344.","journal-title":"Alzheimers Dement"},{"key":"2230_CR119","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillb\u00e4ck","year":"2015","unstructured":"Skillb\u00e4ck T, Farahmand BY, Ros\u00e9n C, Mattsson N, N\u00e4gga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-\u03b21-42 in patients with dementia. Brain. 2015;138:2716\u201331.","journal-title":"Brain."},{"key":"2230_CR120","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","volume":"11","author":"NR Barth\u00e9lemy","year":"2019","unstructured":"Barth\u00e9lemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer\u2019s disease. Front Aging Neurosci. 2019;11:121.","journal-title":"Front Aging Neurosci"},{"key":"2230_CR121","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med. 2020;26:398\u2013407.","journal-title":"Nat Med"},{"key":"2230_CR122","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002;59:1267\u201372.","journal-title":"Arch Neurol"},{"key":"2230_CR123","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/cns.12814","volume":"24","author":"S Ki\u0111emet-Piska\u010d","year":"2018","unstructured":"Ki\u0111emet-Piska\u010d S, Babi\u0107 Leko M, Bla\u017eekovi\u0107 A, Langer Horvat L, Klepac N, Sonicki Z, et al. Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer\u2019s disease and vascular dementia. CNS Neurosci Ther. 2018;24:734\u201340.","journal-title":"CNS Neurosci Ther"},{"key":"2230_CR124","doi-asserted-by":"publisher","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. eBioMedicine. 2022;76:103836.","journal-title":"eBioMedicine."},{"key":"2230_CR125","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/JAD-160448","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Lelental N, Lachmann I, Holzer M, Flach K, Brandner S, et al. Non-phosphorylated tau as a potential biomarker of Alzheimer\u2019s disease: analytical and diagnostic characterization. J Alzheimers Dis. 2017;55:159\u201370.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR126","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodr\u00edguez J, Mil\u00e0-Alom\u00e0 M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol Med. 2020;12:e12921.","journal-title":"EMBO Mol Med"},{"key":"2230_CR127","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome. Mol Neurodegener. 2017;12:63.","journal-title":"Mol Neurodegener"},{"key":"2230_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun. 2020;11:1683.","journal-title":"Nat Commun"},{"key":"2230_CR129","doi-asserted-by":"publisher","first-page":"e15098","DOI":"10.15252\/emmm.202115098","volume":"13","author":"J Lantero-Rodriguez","year":"2021","unstructured":"Lantero-Rodriguez J, Snellman A, Benedet AL, Mil\u00e0-Alom\u00e0 M, Camporesi E, Montoliu-Gaya L, et al. P-tau235: a novel biomarker for staging preclinical Alzheimer\u2019s disease. EMBO Mol Med. 2021;13:e15098.","journal-title":"EMBO Mol Med"},{"key":"2230_CR130","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1212\/WNL.0000000000004860","volume":"90","author":"R La Joie","year":"2018","unstructured":"La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, et al. Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology. 2018;90:E282\u201390.","journal-title":"Neurology."},{"key":"2230_CR131","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al. Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med. 2016;8:338ra66.","journal-title":"Sci Transl Med"},{"key":"2230_CR132","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/brain\/aww139","volume":"139","author":"BA Gordon","year":"2016","unstructured":"Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139:2249\u201360.","journal-title":"Brain."},{"key":"2230_CR133","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaneurol.2019.4749","volume":"77","author":"PF Meyer","year":"2020","unstructured":"Meyer PF, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S, ADNI Investigators. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurol. 2020;77:508\u201316.","journal-title":"JAMA Neurol"},{"key":"2230_CR134","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s00259-020-04758-2","volume":"47","author":"EE Wolters","year":"2020","unstructured":"Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, et al. Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47:2866\u201378.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2230_CR135","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/biom13020290","volume":"13","author":"Z Mohammadi","year":"2023","unstructured":"Mohammadi Z, Alizadeh H, Marton J, Cumming P. The sensitivity of tau tracers for the discrimination of Alzheimer\u2019s disease patients and healthy controls by PET. Biomolecules. 2023;13:290.","journal-title":"Biomolecules."},{"key":"2230_CR136","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau-PET and amyloid-PET. Alzheimers Dement. 2018;14:989\u201397.","journal-title":"Alzheimers Dement"},{"key":"2230_CR137","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/alz.12875","volume":"19","author":"R Smith","year":"2023","unstructured":"Smith R, Cullen NC, Pichet Binette A, Leuzy A, Blennow K, Zetterberg H, et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimers Dement. 2023;19:2497\u2013507.","journal-title":"Alzheimers Dement"},{"key":"2230_CR138","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1002\/hbm.22390","volume":"35","author":"M Chiu","year":"2013","unstructured":"Chiu M, Chen Y, Chen T, Yang S, Yang FG, Tseng T, et al. Plasma tau as a window to the brain\u2014negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer\u2019s disease. Hum Brain Mapp. 2013;35:3132\u201342.","journal-title":"Hum Brain Mapp"},{"key":"2230_CR139","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"2230_CR140","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"2230_CR141","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386.","journal-title":"Nat Med"},{"key":"2230_CR142","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. 2020;217:e20200861.","journal-title":"J Exp Med"},{"key":"2230_CR143","doi-asserted-by":"publisher","first-page":"e037520","DOI":"10.1002\/alz.037520","volume":"16","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Palmqvist S, Quiroz YT, Lopera F, Stomrud E, Su Y, et al. Phospho-tau217 and phospho-tau181 in plasma and CSF as biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 2020;16:e037520.","journal-title":"Alzheimers Dement"},{"key":"2230_CR144","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362.","journal-title":"Nat Med"},{"key":"2230_CR145","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"2230_CR146","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, et al. Plasma tau levels in Alzheimer\u2019s disease. Alzheimers Res Ther. 2013;5:9.","journal-title":"Alzheimers Res Ther"},{"key":"2230_CR147","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/nan.12378","volume":"43","author":"H Zetterberg","year":"2017","unstructured":"Zetterberg H. Review: Tau in biofluids\u2014relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol. 2017;43:194\u20139.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2230_CR148","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","volume":"74","author":"MM Mielke","year":"2017","unstructured":"Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, Knopman DS, et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging. JAMA Neurol. 2017;74:1073\u201380.","journal-title":"JAMA Neurol"},{"key":"2230_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09009-3","volume":"7","author":"SY Yang","year":"2017","unstructured":"Yang SY, Chiu MJ, Chen TF, Lin CH, Jeng JS, Tang SC, et al. Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Sci Rep. 2017;7:9304.","journal-title":"Sci Rep"},{"key":"2230_CR150","doi-asserted-by":"publisher","first-page":"205031211559825","DOI":"10.1177\/2050312115598250","volume":"3","author":"KB Shanthi","year":"2015","unstructured":"Shanthi KB, Krishnan S, Rani P. A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer\u2019s disease. SAGE Open Med. 2015;3:2050312115598250.","journal-title":"SAGE Open Med"},{"key":"2230_CR151","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/jnnp.2008.167791","volume":"80","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer\u2019s disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry. 2009;80:966\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2230_CR152","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol"},{"key":"2230_CR153","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/jpm10030085","volume":"10","author":"K Zou","year":"2020","unstructured":"Zou K, Abdullah M, Michikawa M. Current biomarkers for Alzheimer\u2019s disease: from CSF to blood. J Pers Med. 2020;10:85.","journal-title":"J Pers Med"},{"key":"2230_CR154","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, Fern\u00e1ndez-Lebrero A, Garc\u00eda-Escobar G, Gonz\u00e1lez-Ortiz F, et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2023;19:1913\u201324.","journal-title":"Alzheimers Dement"},{"key":"2230_CR155","first-page":"483","volume":"11","author":"S Fossati","year":"2019","unstructured":"Fossati S, Ramos Cejudo J, Debure L, Pirraglia E, Sone JY, Li Y, et al. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 2019;11:483\u201392.","journal-title":"Alzheimers Dement"},{"key":"2230_CR156","doi-asserted-by":"crossref","unstructured":"Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med. 2021;13:e14398.","DOI":"10.15252\/emmm.202114398"},{"key":"2230_CR157","doi-asserted-by":"publisher","first-page":"e055515","DOI":"10.1002\/alz.055515","volume":"17","author":"C Tissot","year":"2021","unstructured":"Tissot C, Kunach P, Therriault J, Lussier FZ, Benedet AL, Chamoun M, et al. Discrepancy between plasma pTau181 and tau-PET statuses. Alzheimers Dement. 2021;17:e055515.","journal-title":"Alzheimers Dement"},{"key":"2230_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21145007","volume":"21","author":"E Nam","year":"2020","unstructured":"Nam E, Lee YB, Moon C, Chang KA. Serum tau proteins as potential biomarkers for the assessment of alzheimer\u2019s disease progression. Int J Mol Sci. 2020;21:1\u201320.","journal-title":"Int J Mol Sci"},{"key":"2230_CR159","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-022-01011-w","volume":"14","author":"PR Kac","year":"2022","unstructured":"Kac PR, Gonzalez-Ortiz F, Simr\u00e9n J, Dewit N, Vanmechelen E, Zetterberg H, et al. Diagnostic value of serum versus plasma phospho-tau for Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:65.","journal-title":"Alzheimers Res Ther"},{"key":"2230_CR160","first-page":"313","volume":"21","author":"IM Kvetnoy","year":"2000","unstructured":"Kvetnoy IM, Hernandez-Yago J, Kvetnaia TV, Kh V, Malinin VV, Yarilin AA, et al. Tau-protein expression in human blood lymphocytes: a promising marker. Neuroendocrinol Lett. 2000;21:313\u20138.","journal-title":"Neuroendocrinol Lett"},{"key":"2230_CR161","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/JAD-2011-101641","volume":"25","author":"K Neumann","year":"2011","unstructured":"Neumann K, Far\u00edas G, Slachevsky A, Perez P, Maccioni RB. Human platelets tau: a potential peripheral marker for Alzheimer\u2019s disease. J Alzheimers Dis. 2011;25:103\u20139.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR162","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","volume":"11","author":"MS Fiandaca","year":"2015","unstructured":"Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al. Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement. 2015;11:600\u20137.e1.","journal-title":"Alzheimers Dement"},{"key":"2230_CR163","first-page":"63","volume":"3","author":"CN Winston","year":"2016","unstructured":"Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement. 2016;3:63\u201372.","journal-title":"Alzheimers Dement"},{"key":"2230_CR164","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/ijms19030663","volume":"19","author":"FX Guix","year":"2018","unstructured":"Guix FX, Corbett GT, Cha DJ, Mustapic M, Liu W, Mengel D, et al. Detection of aggregation-competent tau in neuron-derived extracellular vesicles. Int J Mol Sci. 2018;19:663.","journal-title":"Int J Mol Sci"},{"key":"2230_CR165","doi-asserted-by":"publisher","first-page":"M64","DOI":"10.1093\/gerona\/57.1.M64","volume":"57","author":"H Hattori","year":"2002","unstructured":"Hattori H, Matsumoto M, Iwai K, Tsuchiya H, Miyauchi E, Takasaki M, et al. The \u03c4 protein of oral epithelium increases in Alzheimer\u2019s disease. J Gerontol Ser A 2002;57:M64\u201370.","journal-title":"J Gerontol Ser A"},{"key":"2230_CR166","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3389\/fneur.2017.00554","volume":"8","author":"LF Arredondo","year":"2017","unstructured":"Arredondo LF, Aranda-Romo S, Rodr\u00edguez-Leyva I, Chi-Ahumada E, Saikaly SK, Portales-P\u00e9rez DP, et al. Tau protein in oral mucosa and cognitive state: a cross-sectional study. Front Neurol. 2017;8:554.","journal-title":"Front Neurol"},{"key":"2230_CR167","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3233\/JAD-2011-110731","volume":"27","author":"M Shi","year":"2011","unstructured":"Shi M, Sui YT, Peskind ER, Li G, Hwang H, Devic I, et al. Salivary tau species are potential biomarkers of Alzheimer disease. J Alzheimers Dis. 2011;27:299\u2013305.","journal-title":"J Alzheimers Dis"},{"key":"2230_CR168","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bj.2018.03.004","volume":"41","author":"R Farah","year":"2018","unstructured":"Farah R, Haraty H, Salame Z, Fares Y, Ojcius DM, Sadier NS, et al. Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed J. 2018;41:63\u201387.","journal-title":"Biomed J"},{"key":"2230_CR169","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neurobiolaging.2018.06.014","volume":"70","author":"NJ Ashton","year":"2018","unstructured":"Ashton NJ, Ide M, Sch\u00f6ll M, Blennow K, Lovestone S, Hye A, et al. No association of salivary total tau concentration with Alzheimer\u2019s disease. Neurobiol Aging. 2018;70:125\u20137.","journal-title":"Neurobiol Aging"},{"key":"2230_CR170","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386:896\u2013912.","journal-title":"Lancet."},{"key":"2230_CR171","first-page":"2076942","volume":"2020","author":"C Fang","year":"2020","unstructured":"Fang C, Lv L, Mao S, Dong H, Liu B. Cognition deficits in Parkinson\u2019s disease: mechanisms and treatment. Parkinsons Dis. 2020;2020:2076942.","journal-title":"Parkinsons Dis"},{"key":"2230_CR172","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ana.21157","volume":"62","author":"CP Zabetian","year":"2007","unstructured":"Zabetian CP, Hutter CM, Factor SA, Nutt JG, Higgins DS, Griffith A, et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson\u2019s disease. Ann Neurol. 2007;62:137\u201344.","journal-title":"Ann Neurol"},{"key":"2230_CR173","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mds.24946","volume":"27","author":"JF Morley","year":"2012","unstructured":"Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, et al. Genetic influences on cognitive decline in Parkinson\u2019s disease. Mov Disord. 2012;27:512\u20138.","journal-title":"Mov Disord"},{"key":"2230_CR174","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.21192","volume":"62","author":"A Goris","year":"2007","unstructured":"Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJG, Brown J, et al. Tau and \u03b1-synuclein in susceptibility to, and dementia in, Parkinson\u2019s disease. Ann Neurol. 2007;62:145\u201353.","journal-title":"Ann Neurol"},{"key":"2230_CR175","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/archneurol.2011.17","volume":"68","author":"N Set\u00f3-Salvia","year":"2011","unstructured":"Set\u00f3-Salvia N, Clarim\u00f3n J, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Combarros O, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol. 2011;68:359\u201364.","journal-title":"Arch Neurol"},{"key":"2230_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0765-8","volume":"7","author":"BR Smith","year":"2019","unstructured":"Smith BR, Nelson KM, Kemper LJ, Leinonen-Wright K, Petersen A, Keene CD, et al. A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease. Acta Neuropathol Commun 2019;7:124.","journal-title":"Acta Neuropathol Commun"},{"key":"2230_CR177","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00401-002-0563-3","volume":"104","author":"JE Duda","year":"2002","unstructured":"Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VMY, et al. Concurrence of \u03b1-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 2002;104:7\u201311.","journal-title":"Acta Neuropathol"},{"key":"2230_CR178","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ana.25060","volume":"82","author":"DR Schonhaut","year":"2017","unstructured":"Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD, et al. 18F-flortaucipir tau PET distinguishes established progressive supranuclear palsy from controls and Parkinson\u2019s disease: a multicenter study. Ann Neurol. 2017;82:622\u201334.","journal-title":"Ann Neurol"},{"key":"2230_CR179","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","volume":"73","author":"S Gomperts","year":"2016","unstructured":"Gomperts S, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, et al. Tau PET imaging in the Lewy body diseases. JAMA Neurol. 2016;73:1334\u201341.","journal-title":"JAMA Neurol"},{"key":"2230_CR180","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/brain\/aww098","volume":"139","author":"AK Hansen","year":"2016","unstructured":"Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, et al. In vivo imaging of neuromelanin in Parkinson\u2019s disease using 18F-AV-1451 PET. Brain. 2016;139:2039\u201349.","journal-title":"Brain."},{"key":"2230_CR181","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00429-017-1507-y","volume":"223","author":"S Coakeley","year":"2018","unstructured":"Coakeley S, Cho SS, Koshimori Y, Rusjan P, Ghadery C, Kim J, et al. [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. Brain Struct Funct. 2018;223:589\u201395.","journal-title":"Brain Struct Funct"},{"key":"2230_CR182","doi-asserted-by":"crossref","unstructured":"Marquie M, Verwer E, Meltzer A, Kim S, Aguero C, Gonzalez J, et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson\u2019s case. Acta Neuropathol Commun. 2017;5:75.","DOI":"10.1186\/s40478-017-0482-0"},{"key":"2230_CR183","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3233\/JPD-191774","volume":"10","author":"AK Hansen","year":"2020","unstructured":"Hansen AK, Parbo P, Ismail R, \u00d8stergaard K, Brooks DJ, Borghammer P. Tau tangles in Parkinson\u2019s disease: a 2-year follow-up flortaucipir PET study. J Parkinsons Dis. 2020;10:161\u201371.","journal-title":"J Parkinsons Dis"},{"key":"2230_CR184","doi-asserted-by":"publisher","first-page":"646440","DOI":"10.3389\/fnagi.2021.646440","volume":"13","author":"CH Li","year":"2021","unstructured":"Li CH, Chen TF, Chiu MJ, Yen RF, Shih MC, Lin CH. Integrated 18F-T807 tau PET, structural MRI, and plasma tau in tauopathy neurodegenerative disorders. Front Aging Neurosci. 2021;13:646440.","journal-title":"Front Aging Neurosci"},{"key":"2230_CR185","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/mds.26961","volume":"32","author":"AK Hansen","year":"2017","unstructured":"Hansen AK, Damholdt MF, Fedorova TD, Knudsen K, Parbo P, Ismail R, et al. In Vivo cortical tau in Parkinson\u2019s disease using 18F-AV-1451 positron emission tomography. Mov Disord. 2017;32:922\u20137.","journal-title":"Mov Disord"},{"key":"2230_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23041-x","volume":"8","author":"R Smith","year":"2018","unstructured":"Smith R, Sch\u00f6ll M, Londos E, Ohlsson T, Hansson O. 18F-AV-1451 in Parkinson\u2019s disease with and without dementia and in dementia with Lewy bodies. Sci Rep. 2018;8:4717.","journal-title":"Sci Rep"},{"key":"2230_CR187","unstructured":"Michael J. Fox Foundation for Parkinson\u2019s Research. Assessment of brain tau burden in participants with Parkinson\u2019s disease in the PPMI Study (PPMI Tau PET Imaging). Report No.: NCT04906590. clinicaltrials.gov; 2021."},{"key":"2230_CR188","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/mds.29273","volume":"38","author":"Y Tang","year":"2023","unstructured":"Tang Y, Li L, Hu T, Jiao F, Han L, Li S, et al. In vivo 18F-florzolotau tau positron emission tomography imaging in Parkinson\u2019s disease dementia. Mov Disord. 2023;38:147\u201352.","journal-title":"Mov Disord"},{"key":"2230_CR189","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/mds.27284","volume":"33","author":"N Abbasi","year":"2018","unstructured":"Abbasi N, Mohajer B, Abbasi S, Hasanabadi P, Abdolalizadeh A, Rajimehr R. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson\u2019s disease. Mov Disord. 2018;33:431\u20139.","journal-title":"Mov Disord"},{"key":"2230_CR190","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","volume":"131","author":"JH Kang","year":"2016","unstructured":"Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s Progression Markers Initiative study. Acta Neuropathol. 2016;131:935\u201349.","journal-title":"Acta Neuropathol"},{"key":"2230_CR191","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00702-010-0462-z","volume":"117","author":"HP Vranov\u00e1","year":"2010","unstructured":"Vranov\u00e1 HP, Mare\u0161 J, Nevrl\u00fd M, Stejskal D, Zapletalov\u00e1 J, Hlu\u0161t\u00edk P, et al. CSF markers of neurodegeneration in Parkinson\u2019s disease. J Neural Transm. 2010;117:1177\u201381.","journal-title":"J Neural Transm"},{"key":"2230_CR192","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-D\u00f6ring F, Trenkwalder C, Schlossmacher MG. \u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230\u201340.","journal-title":"Lancet Neurol"},{"key":"2230_CR193","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","volume":"89","author":"B Mollenhauer","year":"2017","unstructured":"Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, et al. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. 2017;89:1959\u201369.","journal-title":"Neurology."},{"key":"2230_CR194","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4137\/BMI.S11422","volume":"8","author":"CL Maarouf","year":"2013","unstructured":"Maarouf CL, Beach TG, Adler CH, Malek-Ahmadi M, Kokjohn TA, Dugger BN, et al. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson\u2019s disease cases lacking Alzheimer\u2019s disease pathology. Biomark Insights. 2013;8:19\u201328.","journal-title":"Biomark Insights"},{"key":"2230_CR195","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","volume":"16","author":"A Schrag","year":"2017","unstructured":"Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet Neurol. 2017;16:66\u201375.","journal-title":"Lancet Neurol"},{"key":"2230_CR196","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/mds.26578","volume":"31","author":"S Hall","year":"2016","unstructured":"Hall S, Surova Y, \u00d6hrfelt A, Blennow K, Zetterberg H, Hansson O. Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease. Mov Disord. 2016;31:898\u2013905.","journal-title":"Mov Disord"},{"key":"2230_CR197","first-page":"1277","volume":"70","author":"JH Kang","year":"2013","unstructured":"Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70:1277\u201387.","journal-title":"JAMA Neurol"},{"key":"2230_CR198","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neulet.2010.10.015","volume":"487","author":"Y Compta","year":"2011","unstructured":"Compta Y, Ezquerra M, Mu\u00f1oz E, Tolosa E, Valldeoriola F, Rios J, et al. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal \u03b2-amyloid in Parkinson disease. Neurosci Lett. 2011;487:169\u201373.","journal-title":"Neurosci Lett"},{"key":"2230_CR199","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","volume":"21","author":"C Liu","year":"2015","unstructured":"Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, et al. CSF tau and tau\/A\u03b242 predict cognitive decline in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21:271\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"2230_CR200","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s10072-017-3088-1","volume":"38","author":"X Hu","year":"2017","unstructured":"Hu X, Yang Y, Gong D. Changes of cerebrospinal fluid A\u03b242, t-tau, and p-tau in Parkinson\u2019s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis. Neurol Sci. 2017;38:1953\u201361.","journal-title":"Neurol Sci"},{"key":"2230_CR201","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s12031-020-01776-5","volume":"71","author":"L Pan","year":"2021","unstructured":"Pan L, Meng L, He M, Zhang Z. Tau in the pathophysiology of Parkinson\u2019s disease. J Mol Neurosci. 2021;71:2179\u201391.","journal-title":"J Mol Neurosci"},{"key":"2230_CR202","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/mds.23287","volume":"25","author":"TJ Montine","year":"2010","unstructured":"Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF A\u03b242 and tau in Parkinson\u2019s disease with cognitive impairment. Mov Disord. 2010;25:2682\u20135.","journal-title":"Mov Disord"},{"key":"2230_CR203","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/jnnp.2009.199950","volume":"81","author":"G Alves","year":"2010","unstructured":"Alves G, Br\u00f8nnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, et al. CSF amyloid-\u03b2 and tau proteins, and cognitive performance, in early and untreated Parkinson\u2019s disease: the Norwegian ParkWest study. J Neurol, Neurosurg Psychiatry. 2010;81:1080\u20136.","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"2230_CR204","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/mds.25282","volume":"28","author":"MK Beyer","year":"2013","unstructured":"Beyer MK, Alves G, Hwang KS, Babakchanian S, Bronnick KS, Chou YY, et al. Cerebrospinal fluid A\u03b2 levels correlate with structural brain changes in Parkinson\u2019s disease. Mov Disord. 2013;28:302\u201310.","journal-title":"Mov Disord"},{"key":"2230_CR205","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00702-011-0708-4","volume":"119","author":"H P\u0159ikrylov\u00e1 Vranov\u00e1","year":"2012","unstructured":"P\u0159ikrylov\u00e1 Vranov\u00e1 H, Mare\u0161 J, Hlu\u0161t\u00edk P, Nevrl\u00fd M, Stejskal D, Zapletalov\u00e1 J, et al. Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson\u2019s disease. J Neural Transm. 2012;119:353\u201362.","journal-title":"J Neural Transm"},{"key":"2230_CR206","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000094871","volume":"22","author":"B Mollenhauer","year":"2006","unstructured":"Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson\u2019s disease dementia. Dement Geriatr Cogn Disord. 2006;22:200\u20138.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2230_CR207","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fneur.2018.00560","volume":"9","author":"M Dolatshahi","year":"2018","unstructured":"Dolatshahi M, Pourmirbabaei S, Kamalian A, Ashraf-Ganjouei A, Yaseri M, Aarabi MH. Longitudinal alterations of alpha-synuclein, amyloid beta, total, and phosphorylated tau in cerebrospinal fluid and correlations between their changes in Parkinson\u2019s disease. Front Neurol. 2018;9:560.","journal-title":"Front Neurol"},{"key":"2230_CR208","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/mds.22594","volume":"24","author":"Y Compta","year":"2009","unstructured":"Compta Y, Mart\u00ed MJ, Ibarretxe-Bilbao N, Junqu\u00e9 C, Valldeoriola F, Mu\u00f1oz E, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson\u2019s disease. Mov Disord. 2009;24:2203\u201310.","journal-title":"Mov Disord"},{"key":"2230_CR209","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.biopsych.2008.02.016","volume":"64","author":"L Parnetti","year":"2008","unstructured":"Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D\u2019Amore C, et al. Cerebrospinal fluid biomarkers in Parkinson\u2019s disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008;64:850\u20135.","journal-title":"Biol Psychiatry"},{"key":"2230_CR210","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.pneurobio.2011.09.002","volume":"95","author":"C Henchcliffe","year":"2011","unstructured":"Henchcliffe C, Dodel R, Beal MF. Biomarkers of Parkinson\u2019s disease and dementia with Lewy bodies. Prog Neurobiol. 2011;95:601\u201313.","journal-title":"Prog Neurobiol"},{"key":"2230_CR211","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00406-018-0928-9","volume":"270","author":"K Gmitterov\u00e1","year":"2020","unstructured":"Gmitterov\u00e1 K, Gawinecka J, Llorens F, Varges D, Valkovi\u010d P, Zerr I. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson\u2019s disease dementia. Eur Arch Psychiatry Clin Neurosci. 2020;270:461\u201370.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2230_CR212","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jns.2014.05.052","volume":"343","author":"HP Vranov\u00e1","year":"2014","unstructured":"Vranov\u00e1 HP, H\u00e9nykov\u00e1 E, Kaiserov\u00e1 M, Men\u0161\u00edkov\u00e1 K, Va\u0161t\u00edk M, Mare\u0161 J, et al. Tau protein, beta-amyloid1\u201342 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci. 2014;343:120\u20134.","journal-title":"J Neurol Sci"},{"key":"2230_CR213","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.parkreldis.2012.04.028","volume":"18","author":"Y Compta","year":"2012","unstructured":"Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junqu\u00e9 C, Bargall\u00f3 N, Tolosa E, et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson\u2019s disease and related dementia. Parkinsonism Relat Disord. 2012;18:941\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"2230_CR214","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fnagi.2018.00123","volume":"10","author":"CH Lin","year":"2018","unstructured":"Lin CH, Yang SY, Horng HE, Yang CC, Chieh JJ, Chen HH, et al. Plasma biomarkers differentiate Parkinson\u2019s disease from atypical Parkinsonism syndromes. Front Aging Neurosci. 2018;10:123.","journal-title":"Front Aging Neurosci"},{"key":"2230_CR215","doi-asserted-by":"crossref","unstructured":"Batzu L, Rota S, Hye A, Heslegrave A, Trivedi D, Gibson LL, et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8:154.","DOI":"10.1038\/s41531-022-00384-x"},{"key":"2230_CR216","first-page":"513","volume":"5","author":"M Busra","year":"2021","unstructured":"Busra M, Syafrita Y, Permana H. Relationship of serum tau levels with cognitive functions and factors affecting the cognitive function decrease in Parkinson\u2019s disease patients. Biosci Med J Biomed Transl Res. 2021;5:513\u20139.","journal-title":"Biosci Med J Biomed Transl Res"},{"key":"2230_CR217","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3889\/oamjms.2022.7940","volume":"10","author":"Y Syafrita","year":"2022","unstructured":"Syafrita Y, Istarini A, Busra M, Indra S, Susanti R. Relationship between plasma level of beta-amyloid, alpha-synuclein, and tau protein with cognitive impairment in Parkinson disease. Open Access Maced J Med Sci. 2022;10:663\u20137.","journal-title":"Open Access Maced J Med Sci"},{"key":"2230_CR218","doi-asserted-by":"publisher","first-page":"115","DOI":"10.17219\/acem\/112058","volume":"29","author":"J Chojdak-\u0141ukasiewicz","year":"2020","unstructured":"Chojdak-\u0141ukasiewicz J, Ma\u0142odobra-Mazur M, Zimny A, Noga L, Paradowski B. Plasma tau protein and A\u03b242 level as markers of cognitive impairment in patients with Parkinson\u2019s disease. Adv Clin Exp Med. 2020;29:115\u201321.","journal-title":"Adv Clin Exp Med"},{"key":"2230_CR219","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/ane.13517","volume":"145","author":"WT Lin","year":"2022","unstructured":"Lin WT, Shaw JS, Cheng FY, Chen PH. Plasma total tau predicts executive dysfunction in Parkinson\u2019s disease. Acta Neurol Scand. 2022;145:30\u20137.","journal-title":"Acta Neurol Scand"},{"key":"2230_CR220","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","volume":"12","author":"NC Chen","year":"2020","unstructured":"Chen NC, Chen HL, Li SH, Chang YH, Chen MH, Tsai NW, et al. Plasma levels of \u03b1-synuclein, A\u03b2-40 and T-tau as biomarkers to predict cognitive impairment in Parkinson\u2019s disease. Front Aging Neurosci. 2020;12:112.","journal-title":"Front Aging Neurosci"},{"key":"2230_CR221","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/brain\/awp245","volume":"132","author":"CH Williams-Gray","year":"2009","unstructured":"Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson\u2019s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958\u201369.","journal-title":"Brain."},{"key":"2230_CR222","doi-asserted-by":"crossref","unstructured":"Schirinzi T, Zenuni H, Grillo P, Bovenzi R, Guerrera G, Gargano F, et al. Tau and amyloid-\u03b2 peptides in serum of patients with Parkinson\u2019s disease: correlations with CSF levels and clinical parameters. Front Neurol. 2022;13:748599.","DOI":"10.3389\/fneur.2022.748599"},{"key":"2230_CR223","doi-asserted-by":"publisher","first-page":"e21895","DOI":"10.1096\/fj.202100787R","volume":"35","author":"CC Chung","year":"2021","unstructured":"Chung CC, Chan L, Chen JH, Bamodu OA, Chiu HW, Hong CT. Plasma extracellular vesicles tau and \u03b2-amyloid as biomarkers of cognitive dysfunction of Parkinson\u2019s disease. FASEB J. 2021;35:e21895.","journal-title":"FASEB J"},{"key":"2230_CR224","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/brain\/awac258","volume":"146","author":"J Blommer","year":"2023","unstructured":"Blommer J, Pitcher T, Mustapic M, Eren E, Yao PJ, Vreones MP, et al. Extracellular vesicle biomarkers for cognitive impairment in Parkinson\u2019s disease. Brain. 2023;146:195\u2013208.","journal-title":"Brain."},{"key":"2230_CR225","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ana.26550","volume":"93","author":"MI De Bartolo","year":"2023","unstructured":"De Bartolo MI, Vivacqua G, Belvisi D, Mancinelli R, Fabbrini A, Manzo N, et al. A combined panel of salivary biomarkers in de novo Parkinson\u2019s disease. Ann Neurol. 2023;93:446\u201359.","journal-title":"Ann Neurol"},{"key":"2230_CR226","volume-title":"StatPearls [Internet].","author":"A Georges","year":"2023","unstructured":"Georges A, Das JM. Traumatic brain injury. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"2230_CR227","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3233\/NRE-2007-22502","volume":"22","author":"AA Hyder","year":"2007","unstructured":"Hyder AA, Wunderlich CA, Puvanachandra P, Gururaj G, Kobusingye OC. The impact of traumatic brain injuries: a global perspective. NeuroRehabilitation. 2007;22:341\u201353.","journal-title":"NeuroRehabilitation."},{"key":"2230_CR228","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1089\/neu.2014.3548","volume":"32","author":"R Rubenstein","year":"2015","unstructured":"Rubenstein R, Chang B, Davies P, Wagner AK, Robertson CS, Wang KKW. A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids. J Neurotrauma. 2015;32:342\u201352.","journal-title":"J Neurotrauma"},{"key":"2230_CR229","doi-asserted-by":"crossref","unstructured":"Cristofori I, Levin HS. Traumatic brain injury and cognition. In: Grafman J, Salazar AM, editors. Handbook of clinical neurology. Vol. 128. Elsevier; 2015. p. 579\u2013611.","DOI":"10.1016\/B978-0-444-63521-1.00037-6"},{"key":"2230_CR230","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0006-8993(02)02920-7","volume":"947","author":"FP Zemlan","year":"2002","unstructured":"Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, et al. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res. 2002;947:131\u20139.","journal-title":"Brain Res"},{"key":"2230_CR231","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/OAEM.S217424","volume":"12","author":"A Forouzan","year":"2020","unstructured":"Forouzan A, Motamed H, Delirrooyfard A, Zallaghi S. Serum cleaved tau protein and clinical outcome in patients with minor head trauma. Open Access Emerg Med. 2020;12:7\u201312.","journal-title":"Open Access Emerg Med"},{"key":"2230_CR232","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/0268869021000030285","volume":"16","author":"DA Chatfield","year":"2002","unstructured":"Chatfield DA, Zemlan FP, Day DJ, Menon DK. Discordant temporal patterns of S100 \u03b2 and cleaved tau protein elevation after head injury: a pilot study. Br J Neurosurg. 2002;16:471\u20136.","journal-title":"Br J Neurosurg"},{"key":"2230_CR233","doi-asserted-by":"publisher","first-page":"e1131","DOI":"10.1212\/WNL.0000000000200857","volume":"99","author":"AJ Hicks","year":"2022","unstructured":"Hicks AJ, Ponsford JL, Spitz G, Dore V, Krishnadas N, Roberts C, et al. \u03b2-Amyloid and tau imaging in chronic traumatic brain injury: a cross-sectional study. Neurology. 2022;99:e1131\u201341.","journal-title":"Neurology."},{"key":"2230_CR234","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1750-3639.2011.00513.x","volume":"22","author":"VE Johnson","year":"2011","unstructured":"Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid\u2010beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 2011;22:142\u20139.","journal-title":"Brain Pathol"},{"key":"2230_CR235","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1093\/brain\/awz238","volume":"142","author":"K Takahata","year":"2019","unstructured":"Takahata K, Kimura Y, Sahara N, Koga S, Shimada H, Ichise M, et al. PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury. Brain. 2019;142:3265\u201379.","journal-title":"Brain."},{"key":"2230_CR236","doi-asserted-by":"publisher","first-page":"102665","DOI":"10.1016\/j.nicl.2021.102665","volume":"30","author":"N Marklund","year":"2021","unstructured":"Marklund N, Vedung F, Lubberink M, Tegner Y, Johansson J, Blennow K, et al. Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients\u2014a PET\/MR study. Neuroimage Clin. 2021;30:102665.","journal-title":"Neuroimage Clin"},{"key":"2230_CR237","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1212\/01.WNL.0000063313.57292.00","volume":"60","author":"G Franz","year":"2003","unstructured":"Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E, Ulmer H, et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology. 2003;60:1457\u201361.","journal-title":"Neurology."},{"key":"2230_CR238","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1212\/01.wnl.0000242732.06714.0f","volume":"67","author":"M \u00d6st","year":"2006","unstructured":"\u00d6st M, Nyl\u00e9n K, Csajbok L, \u00d6hrfelt AO, Tullberg M, Wikkels\u00f6 C, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67:1600\u20134.","journal-title":"Neurology."},{"key":"2230_CR239","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1089\/neu.2017.5495","volume":"35","author":"MT Caprelli","year":"2018","unstructured":"Caprelli MT, Mothe AJ, Tator CH. Hyperphosphorylated tau as a novel biomarker for traumatic axonal injury in the spinal cord. J Neurotrauma. 2018;35:1929\u201341.","journal-title":"J Neurotrauma"},{"key":"2230_CR240","doi-asserted-by":"publisher","first-page":"e33606","DOI":"10.1371\/journal.pone.0033606","volume":"7","author":"S Neselius","year":"2012","unstructured":"Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in olympic boxing: diagnosis and effects of repetitive head trauma. PLoS ONE. 2012;7:e33606.","journal-title":"PLoS ONE"},{"key":"2230_CR241","doi-asserted-by":"publisher","first-page":"e2717","DOI":"10.1212\/WNL.0000000000007608","volume":"92","author":"F Taghdiri","year":"2019","unstructured":"Taghdiri F, Multani N, Tarazi A, Naeimi SA, Khodadadi M, Esopenko C, et al. Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions. Neurology. 2019;92:e2717\u201326.","journal-title":"Neurology."},{"key":"2230_CR242","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/BF02850342","volume":"23","author":"M Bulut","year":"2006","unstructured":"Bulut M, Koksal O, Dogan S, Bolca N, Ozguc H, Korfali E, et al. Tau protein as a serum marker of brain damage in mild traumatic brain injury: preliminary results. Adv Ther. 2006;23:12\u201322.","journal-title":"Adv Ther"},{"key":"2230_CR243","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jss.2008.12.022","volume":"160","author":"PC Liliang","year":"2010","unstructured":"Liliang PC, Liang CL, Weng HC, Lu K, Wang KW, Chen HJ, et al. Tau proteins in serum predict outcome after severe traumatic brain injury. J Surg Res. 2010;160:302\u20137.","journal-title":"J Surg Res"},{"key":"2230_CR244","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3109\/02699052.2012.750752","volume":"27","author":"S Neselius","year":"2013","unstructured":"Neselius S, Zetterberg H, Blennow K, Randall J, Wilson D, Marcusson J, et al. Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj. 2013;27:425\u201333.","journal-title":"Brain Inj"},{"key":"2230_CR245","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ajem.2008.12.025","volume":"28","author":"A Guzel","year":"2010","unstructured":"Guzel A, Karasalihoglu S, Aylan\u00e7 H, Temiz\u00f6z O, Hi\u00e7d\u00f6nmez T. Validity of serum tau protein levels in pediatric patients with minor head trauma. Am J Emerg Med. 2010;28:399\u2013403.","journal-title":"Am J Emerg Med"},{"key":"2230_CR246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2017.09.008","volume":"280","author":"M Olczak","year":"2017","unstructured":"Olczak M, Niderla-Bieli\u0144ska J, Kwiatkowska M, Samoj\u0142owicz D, Tarka S, Wierzba-Bobrowicz T. Tau protein (MAPT) as a possible biochemical marker of traumatic brain injury in postmortem examination. Forensic Sci Int. 2017;280:1\u20137.","journal-title":"Forensic Sci Int"},{"key":"2230_CR247","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaneurol.2017.0655","volume":"74","author":"R Rubenstein","year":"2017","unstructured":"Rubenstein R, Chang B, Yue JK, Chiu A, Winkler EA, Puccio AM, et al. Comparing plasma phospho tau, total tau, and phospho tau-total tau ratio as acute and chronic traumatic brain injury biomarkers. JAMA Neurol. 2017;74:1063\u201372.","journal-title":"JAMA Neurol"},{"key":"2230_CR248","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/02699050500488207","volume":"20","author":"JJ Bazarian","year":"2006","unstructured":"Bazarian JJ, Zemlan FP, Mookerjee S, Stigbrand T. Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Inj. 2006;20:759\u201365.","journal-title":"Brain Inj"},{"key":"2230_CR249","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3171\/2008.9.JNS08584","volume":"110","author":"N Marklund","year":"2009","unstructured":"Marklund N, Blennow K, Zetterberg H, Ronne-Engstr\u00f6m E, Enblad P, Hillered L. Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury: clinical article. J Neurosurg. 2009;110:1227\u201337.","journal-title":"J Neurosurg"},{"key":"2230_CR250","unstructured":"Ajitkumar A, Jesus OD. Huntington disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"2230_CR251","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RA Roos","year":"2010","unstructured":"Roos RA. Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.","journal-title":"Orphanet J Rare Dis"},{"key":"2230_CR252","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/brain\/aww021","volume":"139","author":"M Gratuze","year":"2016","unstructured":"Gratuze M, Cisbani G, Cicchetti F, Planel E. Is Huntington\u2019s disease a tauopathy? Brain. 2016;139:1014\u201325.","journal-title":"Brain."},{"key":"2230_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.104","volume":"7","author":"F L\u2019Episcopo","year":"2016","unstructured":"L\u2019Episcopo F, Drouin-Ouellet J, Tirolo C, Pulvirenti A, Giugno R, Testa N, et al. GSK-3\u03b2-induced tau pathology drives hippocampal neuronal cell death in Huntington\u2019s disease: involvement of astrocyte\u2013neuron interactions. Cell Death Dis. 2016;7:e2206.","journal-title":"Cell Death Dis"},{"key":"2230_CR254","doi-asserted-by":"publisher","first-page":"580732","DOI":"10.3389\/fneur.2020.580732","volume":"11","author":"M Masnata","year":"2020","unstructured":"Masnata M, Salem S, de Rus Jacquet A, Anwer M, Cicchetti F. Targeting tau to treat clinical features of Huntington\u2019s disease. Front Neurol. 2020;11:580732.","journal-title":"Front Neurol"},{"key":"2230_CR255","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41374-018-0166-9","volume":"99","author":"SU Baskota","year":"2019","unstructured":"Baskota SU, Lopez OL, Greenamyre JT, Kofler J. Spectrum of tau pathologies in Huntington\u2019s disease. Lab Investig. 2019;99:1068\u201377.","journal-title":"Lab Investig"},{"key":"2230_CR256","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/hmg\/ddu421","volume":"24","author":"D Blum","year":"2015","unstructured":"Blum D, Herrera F, Francelle L, Mendes T, Basquin M, Obriot H, et al. Mutant huntingtin alters tau phosphorylation and subcellular distribution. Hum Mol Genet. 2015;24:76\u201385.","journal-title":"Hum Mol Genet"},{"key":"2230_CR257","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biom6010006","volume":"6","author":"G \u0160imi\u0107","year":"2016","unstructured":"\u0160imi\u0107 G, Babi\u0107 Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milo\u0161evi\u0107 N, et al. Tau protein hyperphosphorylation and aggregation in Alzheimer\u2019s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules. 2016;6:6.","journal-title":"Biomolecules."},{"key":"2230_CR258","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JHD-140111","volume":"3","author":"MY Davis","year":"2014","unstructured":"Davis MY, Keene CD, Jayadev S, Bird T. The co-occurrence of Alzheimer\u2019s disease and Huntington\u2019s disease: a neuropathological study of 15 elderly Huntington\u2019s disease subjects. J Huntingt Dis. 2014;3:209\u201317.","journal-title":"J Huntingt Dis"},{"key":"2230_CR259","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40478-019-0764-9","volume":"7","author":"P Liu","year":"2019","unstructured":"Liu P, Smith BR, Huang ES, Mahesh A, Vonsattel JPG, Petersen AJ, et al. A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington\u2019s disease patients. Acta Neuropathol Commun. 2019;7:111.","journal-title":"Acta Neuropathol Commun"},{"key":"2230_CR260","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/nm.4199","volume":"22","author":"X Zhao","year":"2016","unstructured":"Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, et al. Caspase-2 cleavage of tau reversibly impairs memory. Nat Med. 2016;22:1268\u201376.","journal-title":"Nat Med"},{"key":"2230_CR261","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s007020050095","volume":"105","author":"KA Jellinger","year":"1998","unstructured":"Jellinger KA. Alzheimer-type lesions in Huntington\u2019s disease. J Neural Transm. 1998;105:787\u201399.","journal-title":"J Neural Transm"},{"key":"2230_CR262","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1532-5415.1988.tb01807.x","volume":"36","author":"RJ Moss","year":"1988","unstructured":"Moss RJ, Mastri AR, Schut LJ. The coexistence and differentiation of late onset Huntington\u2019s disease and Alzheimer\u2019s disease. A case report and review of the literature. J Am Geriatr Soc. 1988;36:237\u201341.","journal-title":"J Am Geriatr Soc"},{"key":"2230_CR263","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ana.410030616","volume":"3","author":"GC McIntosh","year":"1978","unstructured":"McIntosh GC, Jameson HD, Markesbery WR. Huntington disease associated with Alzheimer disease. Ann Neurol. 1978;3:545\u20138.","journal-title":"Ann Neurol"},{"key":"2230_CR264","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nm.3617","volume":"20","author":"M Fern\u00e1ndez-Nogales","year":"2014","unstructured":"Fern\u00e1ndez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJM, Ferrer I, Rozemuller AJM, et al. Huntington\u2019s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med. 2014;20:881\u20135.","journal-title":"Nat Med"},{"key":"2230_CR265","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","volume":"135","author":"I St-Amour","year":"2018","unstructured":"St-Amour I, Turgeon A, Goupil C, Planel E, H\u00e9bert SS. Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease. Acta Neuropathol. 2018;135:249\u201365.","journal-title":"Acta Neuropathol"},{"key":"2230_CR266","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fncel.2019.00574","volume":"13","author":"M Fern\u00e1ndez-Nogales","year":"2020","unstructured":"Fern\u00e1ndez-Nogales M, Lucas JJ. Altered levels and isoforms of tau and nuclear membrane invaginations in Huntington\u2019s disease. Front Cell Neurosci. 2020;13:574.","journal-title":"Front Cell Neurosci"},{"key":"2230_CR267","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.22204","volume":"24","author":"D Caparros-Lefebvre","year":"2009","unstructured":"Caparros-Lefebvre D, Kerdraon O, Devos D, Dhaenens CM, Blum D, Maurage CA, et al. Association of corticobasal degeneration and Huntington\u2019s disease: can tau aggregates protect Huntingtin toxicity? Mov Disord. 2009;24:1089\u201390.","journal-title":"Mov Disord"},{"key":"2230_CR268","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ymthe.2022.01.020","volume":"30","author":"M Alpaugh","year":"2022","unstructured":"Alpaugh M, Masnata M, de Rus Jacquet A, Lepinay E, Denis HL, Saint-Pierre M, et al. Passive immunization against phosphorylated tau improves features of Huntington\u2019s disease pathology. Mol Ther. 2022;30:1500\u201322.","journal-title":"Mol Ther"},{"key":"2230_CR269","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1212\/WNL.35.2.273","volume":"35","author":"MG Reyes","year":"1985","unstructured":"Reyes MG, Gibbons S. Dementia of the Alzheimer\u2019s type and Huntington\u2019s disease. Neurology. 1985;35:273\u20137.","journal-title":"Neurology."},{"key":"2230_CR270","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.baga.2017.02.038","volume":"8","author":"K Giehl","year":"2017","unstructured":"Giehl K, Reetz K, Dogan I, Werner C, Schulz JB, Hammes J, et al. Tau pathology in Huntington\u2019s disease: a brief in vivo PET-imaging report. Basal Ganglia. 2017;8:13.","journal-title":"Basal Ganglia"},{"key":"2230_CR271","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","volume":"17","author":"R Constantinescu","year":"2011","unstructured":"Constantinescu R, Romer M, Zetterberg H, Rosengren L, Kieburtz K. Increased levels of total tau protein in the cerebrospinal fluid in Huntington\u2019s disease. Parkinsonism Relat Disord. 2011;17:714\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"2230_CR272","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/jnc.13762","volume":"139","author":"I Zerr","year":"2016","unstructured":"Zerr I, B\u00e4hr M. Is there a role of tau in Huntington\u2032s disease? J Neurochem. 2016;139:9\u201310.","journal-title":"J Neurochem"},{"key":"2230_CR273","doi-asserted-by":"publisher","first-page":"e0193492","DOI":"10.1371\/journal.pone.0193492","volume":"13","author":"V Niemel\u00e4","year":"2018","unstructured":"Niemel\u00e4 V, Burman J, Blennow K, Zetterberg H, Larsson A, Sundblom J. Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington\u2019s disease. PLoS ONE. 2018;13:e0193492.","journal-title":"PLoS ONE"},{"key":"2230_CR274","doi-asserted-by":"publisher","first-page":"e0172762","DOI":"10.1371\/journal.pone.0172762","volume":"12","author":"V Niemel\u00e4","year":"2017","unstructured":"Niemel\u00e4 V, Landtblom AM, Blennow K, Sundblom J. Tau or neurofilament light\u2014which is the more suitable biomarker for Huntington\u2019s disease? PLoS ONE. 2017;12:e0172762.","journal-title":"PLoS ONE"},{"key":"2230_CR275","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JRC, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest. 2015;125:1979\u201386.","journal-title":"J Clin Invest"},{"key":"2230_CR276","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jnc.13719","volume":"139","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues FB, Byrne L, McColgan P, Robertson N, Tabrizi SJ, Leavitt BR, et al. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease. J Neurochem. 2016;139:22\u20135.","journal-title":"J Neurochem"},{"key":"2230_CR277","first-page":"565","volume":"23","author":"T Vinther-Jensen","year":"2016","unstructured":"Vinther-Jensen T, B\u00f6rnsen L, Budtz-J\u00f8rgensen E, Ammitzb\u00f8ll C, Larsen IU, Hjermind LE, et al. Cerebrospinal fluid markers in premanifest and manifest Huntington\u2019s disease: evidence of sequential development of neurodegeneration and inflammation. Eur J Neurol. 2016;23:565.","journal-title":"Eur J Neurol"},{"key":"2230_CR278","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.3233\/JAD-190851","volume":"72","author":"N Sawant","year":"2019","unstructured":"Sawant N, Reddy PH. Role of phosphorylated tau and glucose synthase kinase 3 beta in Huntington\u2019s disease progression. J Alzheimers Dis. 2019;72:S177\u201391.","journal-title":"J Alzheimers Dis"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02230-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02230-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02230-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T10:03:35Z","timestamp":1706609015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02230-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":278,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2230"],"URL":"https:\/\/doi.org\/10.1038\/s41380-023-02230-9","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}